BLACK BOX WARNING
- addiction, abuse, misuse
- life-threatening respiratory depression
- neonatal opioid withdrawal
- interaction with benzodiazepines and CNS depressants
tapentadol
Brand: Nucynta, Nucynta ER
⚠ BBW ISMP High Alert Prototype Drug
Drug Class: opioid analgesic (atypical) / centrally acting analgesic
Drug Family: opioid
Subclass: mu-opioid agonist and norepinephrine reuptake inhibitor (MOR-NRI)
Organ Systems: cns
Mechanism of Action
Combines mu-opioid receptor agonism with norepinephrine reuptake inhibition in a single molecule; does not require hepatic activation. The dual mechanism provides analgesia with potentially fewer opioid-mediated side effects (less nausea, constipation) compared to equianalgesic doses of pure opioids, particularly for neuropathic pain.
mu-opioid receptor (MOR)NET (norepinephrine transporter)
Indications
- moderate to severe acute pain
- neuropathic pain associated with diabetic peripheral neuropathy (ER formulation)
Contraindications
- concurrent MAOI use
- significant respiratory depression
- paralytic ileus
Adverse Effects
Common
- nausea
- dizziness
- somnolence
- constipation (less than equianalgesic oxycodone)
- headache
Serious
- respiratory depression
- serotonin syndrome (due to NRI component)
- dependence and addiction
Pharmacokinetics (ADME)
| Absorption | oral bioavailability ~32% due to first-pass; food increases AUC by 25% |
| Distribution | protein binding ~20%; Vd ~540 L |
| Metabolism | primarily glucuronidation to inactive metabolites; minimal CYP involvement — drug interactions via CYP are minimal |
| Excretion | primarily renal (70% as glucuronide conjugates) |
| Half-life | 4 hours |
| Onset | 30-60 minutes |
| Peak | 1.25 hours |
| Duration | 4-6 hours (IR); 12 hours (ER) |
| Protein Binding | 20% |
| Vd | 540 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| MAOIs | serotonin syndrome via NRI component | contraindicated |
| CNS depressants | additive respiratory and CNS depression | major |
| SSRIs/SNRIs | serotonin syndrome risk via noradrenergic component | moderate |
Nursing Considerations
- MAOI contraindication is absolute; tapentadol's NRI mechanism creates the same serotonin syndrome risk as tramadol with concurrent MAOIs.
- Less constipation and nausea compared to equivalent oxycodone doses in clinical trials; this may improve patient adherence and quality of life in chronic pain patients.
- Minimal CYP-mediated drug interactions due to glucuronidation metabolism; this simplifies medication reconciliation in patients on multiple medications.
- Schedule II controlled substance (same as morphine, oxycodone); apply same controlled substance monitoring and documentation protocols.
Clinical Pearls
- Tapentadol is the first approved MOR-NRI (mu-opioid receptor-norepinephrine reuptake inhibitor); its dual mechanism may explain its efficacy in neuropathic pain conditions where pure opioids have limited benefit.
- Despite its theoretical advantages, clinical trials comparing tapentadol to oxycodone have not consistently shown superior efficacy; its clinical niche is primarily neuropathic pain and patients who do not tolerate typical opioid GI side effects.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.